risedronate / Generic mfg. - LARVOL DELTA

Recurrent metatarsal, scapular and acromial fractures during Denosumab therapy in Adult-onset Hypophosphatasia with a pathogenic variant of the ALPL gene and a variant of uncertain significance of the ATRIP Gene (ENDO 2025) - "She was initially started on risedronate at age 61y but due to continued non-traumatic metatarsal fractures teriparatide was recommended...She has been offered treatment with Asfotase alfa (AA). Adult-onset HPP was recognized in a 66-yo female who presented with acromial, scapular and recurrent metatarsal fractures while on denosumab therapy for 4 y for osteoporosis...AA, a human recombinant enzyme replacement therapy was approved for HPP in 2015. Treatment with anabolic agents such as teriparatide and romosozumab has been reported while anti-resorptives such as bisphosphonates and denosumab are contraindicated."

Clinical • Addiction (Opioid and Alcohol) • Endocrine Disorders • Fibromyalgia • Growth Hormone Deficiency (Adult) • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Osteoporosis • Pain • Rheumatology • ALPL • ATRIP

Primary Hyperparathyroidism in a Patient with Osteogenesis Imperfecta Type I and Osteoporosis (ENDO 2025) - "She was diagnosed with osteoporosis after menopause in her early 50s and was started on risedronate...Although some treatments for osteoporosis and OI overlap, we have limited, long-term data on denosumab use...Routine measurement of calcium should be done in patients with OI as these conditions can occur and the diagnosis and opportunity for treatment can be missed. Additional studies are needed to establish this concurrence."

Clinical • Endocrine Disorders • Genetic Disorders • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Otorhinolaryngology • Rheumatology

ANTIRESORPTIVE TREATMENT OF OSTEOPOROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS: DO ORALLY ADMINISTERED DRUGS WORK (EULAR 2025) - "Antiresorptive therapies included alendronate (n=17), zoledronate (n=7), denosumab (n=11), risedronate (n=2), and ibandronate (n=1). Antiresorptive therapy appears effective and safe in patients with SSc. Subgroup analysis suggests that parenteral therapies may be more effective, with denosumab showing the most consistent improvements in axial BMD. Notably, both oral and parenteral antiresorptive drugs were well-tolerated, as no adverse events were observed."

Clinical • Gastrointestinal Disorder • Immunology • Osteoporosis • Rheumatology • Scleroderma • Systemic Sclerosis

ROMOSOZUMAB IN PATIENTS WITH OSTEOPOROSIS: SAFETY AND EFFICACY ANALYSIS IN CLINICAL PRACTICE (EULAR 2025) - "Following romosozumab, the most frequently used therapies were denosumab (44.4%), risedronate (27.8%), zoledronic acid (13.9%), alendronate (5.6%), and teriparatide (2.8%). Romosozumab therapy represents a safe bone-forming treatment option for elderly patients with established classic cardiovascular risk factors. An increase in bone formation markers and a reduction in bone resorption markers were observed in blood tests, along with an improvement in bone mineral density as measured by densitometry. The most commonly used treatment following romosozumab was denosumab, followed by bisphosphonates."

Clinical • Congestive Heart Failure • Diabetes • Dyslipidemia • Genetic Disorders • Heart Failure • Hypertension • Metabolic Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Non-melanoma Skin Cancer • Osteoporosis • Pain • Parotid Gland Cancer • Rheumatology • Skin Cancer • Solid Tumor

SUBTROCHANTERIC FEMORAL FRACTURES (ATYPICAL OR NOT) AND PREVIOUS TREATMENT WITH BISPHOSPHONATE (EULAR 2025) - "In patients with subtrochanteric fracture, 6 had received alendronate, 1 risedronate and 1 denosumab. Subtrocanteric femoral fractures are associated with higher BMI and the use of bisphosphonate or denosumab. Atypical fracture is rare, accounting only 3% of subtrocanteric type."

Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

A MULTICENTRIC CROSS SECTIONAL STUDY EVALUATING THE BONE HEALTH IN YOUNG PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (EULAR 2025) - "A total of 36 (16.7%) patients were exposed to bisphosphonate therapy including Alendronate(17), Ibandronate(4), Risedronate(6), Zoledronate(9), and 13, 3, 4, and 8 patients were detected with low BMD, respectively. This is the first study evaluating the prevalence of low BMD in young patients with SLE in India. Low BMD was observed in 28.12% of patients. In SLE, nephritis and higher cumulative dose of glucocorticoids may contribute to elevated fracture risk."

Clinical • Observational data • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Musculoskeletal Diseases • Nephrology • Orthopedics • Osteoporosis • Rheumatology • Systemic Lupus Erythematosus

Paget's Disease of Bone: Clinical and Epidemiological Profiling of a Portuguese Cohort at a Tertiary Center (EULAR 2025) - "First line treatment was with zoledronate in 60 (75.0%) patients, pamidronate in 8 (10.0%) patients, alendronate in 4 (5.0%) patients, calcitonin in 3 (3.8%) patients, risedronate in 1 (1.3%) patient and denosumab in 1 (1.3%) patient. To the best of our knowledge, this study describes the largest Portuguese cohort of PDB patients. A high prevalence of this disease in rural areas and a high biochemical remission rate after treatment were noted. Patients treated with a non-zoledronate drug as first line therapy had a higher rate of retreatment than patients treated with zoledronate as first line therapy (HR 10.10)."

Clinical • Orthopedics • Rare Diseases

Comparison of the efficacy of 12-month romosozumab followed by 24-month denosumab versus 36-month denosumab or risedronate for glucocorticoid-induced osteoporosis in patients with rheumatic diseases; a randomized prospective study (EULAR 2025) - "The BMD of the lumbar spine, femoral neck, and total hip increased with ROMO-DMAb for 3 years, even under GC therapy. In particular, the BMD of the lumbar spine increased significantly compared to baseline and more than DMAb and BP. Furthermore, no significant differences were observed in the incidence of adverse effects, suggesting that long-term ROMO-DMAb treatment is effective and safe for GIOP."

Clinical • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • COL1A2 • DKK1 • TRAP • WNT3A

Immunological enhancement of micro-nanoparticle formulated with risedronate and zinc as vaccine adjuvant in aged mice. (PubMed, Immun Ageing) - "These findings support Zn-RS as a promising adjuvant candidate for elderly populations, warranting further exploration of its mechanisms and potential applications."

Journal • Preclinical • Herpes Zoster • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Varicella Zoster

Synthesis and Biological Evaluation of 131I-Risedronate with Bone Targeting Activity. (PubMed, Mol Pharm) - "Notably, at 3 days postadministration, significant bone retention was observed, indicating its potential for sustained therapeutic effects. Additionally, its biodistribution and therapeutic effect can be effectively monitored by SPECT/CT imaging."

Journal • Oncology • Solid Tumor

Mitigating gastrointestinal side effects of risedronate sodium: A study on Bletilla striata polysaccharide microneedle patches. (PubMed, Int J Pharm) - "Biochemical markers (BGP, IL-6, CTX-I, TRAP, OPG, and PINP) indicated that RIS-BMNs had anti-osteoporotic effects comparable to oral RIS but without gastrointestinal side effects, as confirmed by H&E staining. Our new transdermal method for RIS could improve adherence in treating postmenopausal osteoporosis."

Adverse events • Journal • Fatigue • Gastrointestinal Disorder • Musculoskeletal Pain • Osteoporosis • Pain • Rheumatology • IL6

Synergistic Induction of Immunogenic Cell Death by Biomineralized Manganese and Bisphosphonates Enhances Anti-PD-L1 Therapy in Triple-Negative Breast Cancer. (PubMed, Int J Nanomedicine) - "By leveraging the doping capacity of hydroxyapatite (HA) for Mn²+ and its high affinity for BPs, we developed MnHARis particles-a biocompatible slow-release system of biomineralized Mn²+ and risedronate (Ris)...Additionally, increased exposure of calreticulin and increased secretion of high mobility group box 1 indicated that MnHARis successfully induced ICD and promoted specific recognition and cross-presentation of damage-associated molecular patterns released by apoptotic tumor cells by activating dendritic cells and pattern recognition receptors, thereby altering TME of TNBC, increasing TILs, and sensitizing TNBC to anti-PD-L1 therapy. MnHARis effectively synergizes Mn²+ and Ris to promote autophagic apoptosis and ICD, increasing TILs and sensitizing TNBC to anti-PD-L1 therapy, thus offering a new therapeutic strategy."

IO biomarker • Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CALR • HMGB1

Osteoporosis medication use over time in the United States and Canada. (PubMed, Osteoporos Int) - "New use of osteoporosis medications remains below pre-2008 levels, and differs between the US and Canada. Future research should aim to understand drivers of decreased use, like changes in the screening strategy used for initial treatment or persisting concerns about adverse effects."

Journal • Osteoporosis • Rheumatology

Risk of jaw osteonecrosis and atypical femoral fracture: how to inform patients with osteoporosis? (PubMed, Ther Umsch) - "Amino-bisphosphonates (BP), such as zoledronate, alendronate, ibandronate or risedronate, and the antibody therapies with denosumab (DMAb) or romosozumab (ROMO) are highly effective therapies for reducing the risk of vertebral fractures and non-vertebral fractures in patients with osteoporosis. This association leads to uncertainty among patients and treating physicians as to how the benefit-risk should be assessed in individual cases. By providing concrete answers to specific questions in connection with these rare events, patients can be informed in a targeted manner."

Journal • Review • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Cost-Effectiveness of Bisphosphonates in Preventing Periprosthetic Fracture After Hip Arthroplasty (AAOS 2025) - "Four bisphosphonates were identified (Alendronate, Ibandronate, Risedronate, and Zoledronate) with annual costs ranging from $10.45-92.56 according to the National Average Drug Acquisition Cost database. If bisphosphonates are clinically efficacious in reducing periprosthetic hip fracture risk, preoperative therapy is an economically viable intervention across a range of medications and baseline fracture rates. Given prior studies have shown strong correlation between osteoporosis undertreatment and periprosthetic fracture risk, our study deems this intervention highly cost-effective."

Cost effectiveness • HEOR • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis. (PubMed, Osteoporos Int) - "In the NMA model, teriparatide and abaloparatide were superior to placebo, raloxifene, and calcitonin in reducing vertebral fracture while teriparatide was further superior to denosumab and risedronate. For non-vertebral fracture, abaloparatide was better than any other treatment while teriparatide was only superior to alendronate or placebo...This review highlights that PTH1 receptor agonists effectively reduce fracture risk, with abaloparatide offering enhanced benefits for non-vertebral and hip fractures compared to teriparatide. Both agents exhibit acceptable safety profiles, suggesting their valuable role in managing osteoporosis, particularly for high-risk patients."

Journal • Retrospective data • Review • Cardiovascular • Endocrine Disorders • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Analysis of Risedronate Analog on Extraction Socket Healing in Mice. (PubMed, In Vivo) - "High bone affinity without potent inhibition of bone resorption does not induce MRONJ-like lesions in mice. These findings suggest that the potent anti-resorptive activity of N-BPs is a key factor in MRONJ development, highlighting the importance of bone turnover suppression in the pathogenesis of this condition."

Journal • Preclinical • TRAP

Tetranuclear and dinuclear Cu(II) complexes with risedronate as anti-Trypanosoma cruzi and anti-Leishmania mexicana agents. Synthesis, crystal structures, and biological evaluation. (PubMed, Dalton Trans) - "Importantly cytotoxicity to VERO cells was minor with the Cu(II)-Ris complexes compared with NaRis. The molecular docking analysis showed significant affinity towards the enzyme farnesyl diphosphate synthase from T. cruzi (TcFPPS), including simulations of the complexes Cu(II) at the TcFPPS binding site."

Journal • Dermatology • Infectious Disease • Oncology

An FDA-approved drug structurally and phenotypically corrects the K210del mutation in genetic cardiomyopathy models. (PubMed, J Clin Invest) - "Systemic administration of risedronate to K210del mice normalized left ventricular ejection fraction. Collectively, these results identify the structural basis for decreased calcium sensitivity in K210del and highlight structural and phenotypic correction as a potential therapeutic strategy in genetic cardiomyopathies."

FDA event • Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Genetic Disorders • Heart Failure

Optimization of Peri-Implant Bone Repair in Estrogen-Deficient Rats on a Cafeteria Diet: The Combined Effects of Systemic Risedronate and Genistein-Functionalized Implants. (PubMed, Materials (Basel)) - "Molecular analysis indicated elevated expression levels of osteocalcin, alkaline phosphatase, and vascular endothelial growth factor in the OVX-CD-RIS/GEN subgroup. In conclusion, the combined treatment of systemic RIS and GEN-functionalized implants significantly enhanced peri-implant bone repair, offering a promising strategy to improve implant outcomes in postmenopausal women with metabolic syndrome."

Journal • Preclinical • Metabolic Disorders • Osteoporosis • Rheumatology • BGLAP

Effects of Sequential Anti-Resorptive Agents on Bone Mineral Density Following Denosumab Withdrawal: A Multicenter Real-World Study in Korea (MAXCARE Study). (PubMed, Endocrinol Metab (Seoul)) - "This retrospective study included 360 patients (low-dose alendronate/calcitriol combination [MXM, n=118], alendronate [ALD, n=53], risedronate [RIS, n=20], ibandronate [IBN, n=30], zoledronic acid [ZOL, n=106], selective estrogen receptor modulator [SERM, n=33]) who received at least 12 months of post-denosumab anti-resorptive therapy. Conversely, RIS, IBN, and SERM did not adequately prevent BMD decline. These findings underscore the importance of selecting the most appropriate sequential antiresorptive therapy in clinical practice to minimize BMD loss and reduce the risk of adverse outcomes."

Journal • Real-world evidence • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Comparative analysis of risedronate and its regioisomers synthesized via microwave-assisted method: bone affinity, cytotoxicity, permeability, and therapeutic potential. (PubMed, Pharmacol Rep) - "The study highlights the potential of the 2-RSD as a more effective treatment for bone diseases. Structural variations in BPs can greatly influence their biological properties, paving the way for the development of improved therapeutic agents."

Journal • Orthopedics • Osteoporosis • Rheumatology

Changing trends in bisphosphonate therapy: a twenty-five-year surveillance in a single US integrated healthcare system. (PubMed, Osteoporos Int) - "In a large primary care population of adults initiating BP, greater treatment of older adults and those with prior fracture highlights the key role of targeted fracture prevention initiatives, sustaining treatment efforts."

Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Effects of Bisphosphonates on OI-Related Hearing Loss (clinicaltrials.gov) - P4 | N=100 | Recruiting | Sponsor: Hospital for Special Surgery, New York | Trial completion date: Nov 2024 ➔ Nov 2025 | Trial primary completion date: Nov 2024 ➔ Nov 2025

Trial completion date • Trial primary completion date • Genetic Disorders • Otorhinolaryngology

Evaluation and analysis of efficacy in bisphosphonate treatment of chronic nonbacterial osteomyelitis. (PubMed, Hua Xi Kou Qiang Yi Xue Za Zhi) - "Bisphosphonate could be used to treat chronic nonbacterial osteomyelitis, which of efficacy were affected by different drug types, dose and frequency of administration. The optimal dose and frequency of administration of pamidronate were 0.5-1 mg/kg (maximum single dose≤60 mg) and once every 3 months, respectively."

Journal • Inflammation